Literature DB >> 24507512

Pathology of multiple sclerosis and related inflammatory demyelinating diseases.

Alexandra Kutzelnigg1, Hans Lassmann2.   

Abstract

This article provides a comprehensive overview of the pathology of multiple sclerosis (MS), including recent insights into its molecular neuropathology and immunology. It shows that all clinical manifestations of relapsing and progressive MS display the same basic features of pathology, such as chronic inflammation, demyelination in the white and gray matter, and diffuse neurodegeneration within the entire central nervous system. However, the individual components of the pathological spectrum vary quantitatively between early relapsing and late progressive MS. Widespread confluent and plaque-like demyelination with oligodendrocyte destruction is the unique pathological hallmark of the disease, but axonal injury and neurodegeneration are additionally present and in part extensive. Remyelination of existing lesions may occur in MS brains; it is extensive in a subset of patients, while it fails in others. Active tissue injury in MS is always associated with inflammation, consistent with T-cell and macrophage infiltration and microglia activation. Recent data suggest that oxidative injury and subsequent mitochondrial damage play a major pathogenetic role in neurodegeneration. Finally we discuss similarities and differences of the pathology between classical MS and other inflammatory demyelinating diseases, such as neuromyelitis optica, concentric sclerosis, or acute disseminated encephalomyelitis.
© 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  B-cells; T-cells; astrocytes; demyelination; macrophages; neurodegeneration; oligodendrocytes; remyelination

Mesh:

Year:  2014        PMID: 24507512     DOI: 10.1016/B978-0-444-52001-2.00002-9

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  93 in total

Review 1.  Microenvironmental regulation of oligodendrocyte replacement and remyelination in spinal cord injury.

Authors:  Arsalan Alizadeh; Soheila Karimi-Abdolrezaee
Journal:  J Physiol       Date:  2016-03-29       Impact factor: 5.182

2.  Activated T cells induce proliferation of oligodendrocyte progenitor cells via release of vascular endothelial cell growth factor-A.

Authors:  Elliot H Choi; Yadi Xu; Marie Medynets; Maria Chiara G Monaco; Eugene O Major; Avindra Nath; Tongguang Wang
Journal:  Glia       Date:  2018-11       Impact factor: 7.452

3.  Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI.

Authors:  J Maranzano; M Dadar; D A Rudko; D De Nigris; C Elliott; J S Gati; S A Morrow; R S Menon; D L Collins; D L Arnold; S Narayanan
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-20       Impact factor: 3.825

4.  Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.

Authors:  Ulrike W Kaunzner; Yeona Kang; Shun Zhang; Eric Morris; Yihao Yao; Sneha Pandya; Sandra M Hurtado Rua; Calvin Park; Kelly M Gillen; Thanh D Nguyen; Yi Wang; David Pitt; Susan A Gauthier
Journal:  Brain       Date:  2019-01-01       Impact factor: 13.501

Review 5.  Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.

Authors:  Maria Pia Sormani; Matteo Pardini
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 6.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 7.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

8.  Accumulation of reactivity to MBP sensitizes TRAIL mediated oligodendrocyte apoptosis in adult sub cortical white matter in a model for human multiple sclerosis.

Authors:  Sajad Mir; Farrah Ali; Deepika Chauhan; Rajesh Arora; Haider A Khan
Journal:  Metab Brain Dis       Date:  2015-10-19       Impact factor: 3.584

9.  Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.

Authors:  Giacomo Lazzarino; Angela M Amorini; Axel Petzold; Claudio Gasperini; Serena Ruggieri; Maria Esmeralda Quartuccio; Giuseppe Lazzarino; Enrico Di Stasio; Barbara Tavazzi
Journal:  Mol Neurobiol       Date:  2016-11-08       Impact factor: 5.590

10.  Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.

Authors:  Norah G Verbout; Xiaolin Yu; Laura D Healy; Kevin G Phillips; Erik I Tucker; András Gruber; Owen J T McCarty; Halina Offner
Journal:  Metab Brain Dis       Date:  2014-05-09       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.